Search Results - "metastasis"

Changing paradigms in anticancer drug development inhibiting angiogenesis in colorectal cancer /

Table of Contents: “…Contents: Targeted therapy for cancer -- Angiogenesis is involved throughout tumour formation, growth and metastasis -- VEGF: molecular characteristics -- VEGF and other signals promote the angiogenic switch in tumours -- Tumour vasculature is abnormal -- VEGF produces immature tortuous vessels dependent on VEGF for survival -- Other features make VEGF an attractive target for anticancer therapy -- RhuMAb VEGF (bevacizumab/Avastin®) -- Significant reduction in microvasculature -- Anti-VEGF antibody improves drug delivery -- Avastin: an anti-VEGF agent for cancer therapy -- Use of Avastin with oxaliplatin-based therapy -- Addition of Avastin to oxaliplatin-based chemotherapy improved best confirmed response -- Study schema and organization.…”
Get full text
Series

Changing paradigms in anticancer drug development inhibiting angiogenesis in colorectal cancer /

Table of Contents: “…Contents: Targeted therapy for cancer -- Angiogenesis is involved throughout tumour formation, growth and metastasis -- VEGF: molecular characteristics -- VEGF and other signals promote the angiogenic switch in tumours -- Tumour vasculature is abnormal -- VEGF produces immature tortuous vessels dependent on VEGF for survival -- Other features make VEGF an attractive target for anticancer therapy -- RhuMAb VEGF (bevacizumab/Avastin®) -- Significant reduction in microvasculature -- Anti-VEGF antibody improves drug delivery -- Avastin: an anti-VEGF agent for cancer therapy -- Use of Avastin with oxaliplatin-based therapy -- Addition of Avastin to oxaliplatin-based chemotherapy improved best confirmed response -- Study schema and organization.…”
Get full text
Series

Changing paradigms in anticancer drug development inhibiting angiogenesis in colorectal cancer /

Table of Contents: “…Contents: Targeted therapy for cancer -- Angiogenesis is involved throughout tumour formation, growth and metastasis -- VEGF: molecular characteristics -- VEGF and other signals promote the angiogenic switch in tumours -- Tumour vasculature is abnormal -- VEGF produces immature tortuous vessels dependent on VEGF for survival -- Other features make VEGF an attractive target for anticancer therapy -- RhuMAb VEGF (bevacizumab/Avastin®) -- Significant reduction in microvasculature -- Anti-VEGF antibody improves drug delivery -- Avastin: an anti-VEGF agent for cancer therapy -- Use of Avastin with oxaliplatin-based therapy -- Addition of Avastin to oxaliplatin-based chemotherapy improved best confirmed response -- Study schema and organization.…”
Get full text
Series